Enhanced Bone Formation in Osteoporotic Mice by a Novel Transplant Combined with Adipose-derived Stem Cells and Platelet-rich Fibrin Releasates

Abstract

<jats:p> Osteoporotic fracture is the main complication of osteoporosis (OP) and accounts for millions of injuries annually. Local intervention by intra-marrow injection has been a good option for preventing osteoporotic bone loss when the osteoporotic femoral fracture has been treated. In this study, tail vein transplantations were examined to evaluate the cell-based therapeutic approach for treating OP with adipose-derived stem cells (ADSCs) and platelet-rich fibrin releasates (PRFr) in an ovariectomized (OVX) mice model. Thirty-six 12-wk-old female ICR mice were randomly divided into six groups: untreated control; sham-operated; OVX-control; OVX-ADSCs; OVX-PRFr; and OVX-ADSCs+PRFr. Starting 8 wk after ovariectomy, the OVX mice received tail vein injections once each week for four consecutive weeks, then were evaluated radiographically and histopathologically 8 wk after the first injection. We also assessed changes to bone trabeculae in the proximal tibial growth plate. In OVX mice treated with ADSCs or PRFr alone, or with a combination of ADSCs and PRFr, the trabecular bone mineral density (BMD), bone volume ratios (BV/TV), and numbers (Tb.N) in the proximal tibia areas were significantly higher than that in the OVX-control group. Significant differences between OVX-treated mice and OVX controls were found for trabecular separation, but not for trabecular thickness. These results indicate that ADSCs or PRFr treatment enhances bone microarchitecture in OP. The treatment of bone loss of OVX mice with ADSCs+PRFr induced greater bone consolidation with bone tissue production ( P &lt; 0.01) when compared to the others. Thus, we conclude that the transplantation of ADSCs combined with PRFr might provide an alternative strategy for the treatment of various bone disorders in OP with an unlimited source of cells and releasates. </jats:p>

The role of PRP as biological stimulator for cartilage regeneration: An experimental prospective study

“…Studies on degenerative cartilaginous tissue and osteoporosis have shown that PRP can repair damaged tissue (Oliver et al, 2015;Sheu et al, 2020;Fortier et al, 2010). Mesenchymal stem cells (MSCs) in BMAC suggest that they may have significant regenerative properties, even for avascular tissues like articular cartilage.…”

Evaluation of the Efficacy of Stem Cell Therapy in Ovariectomized Osteoporotic Rats Based on Micro-CT and Dual-Energy X-Ray Absorptiometry: A Systematic Review and Meta-Analysis

“…Elseweidy et al [26] demonstrated that the combination of MSC and the antioxidant resveratrol was more effective in increasing bone mass and improving osteoporosis than treatment alone. Some studies had shown that the combination of plateletrich fibrin releasates (PRFr) and BMSCs [27] or ADSCs 10 Stem Cells International [28] could reduce bone loss in OVX osteoporotic mice. Based on the above findings, we can find that stem cell transplantation holds promise as a potential treatment for osteoporosis.…”

The Potential Therapeutic Effects of Platelet-Derived Biomaterials on Osteoporosis: A Comprehensive Review of Current Evidence

“…Several studies have demonstrated the effectiveness of platelet concentrates for the treatment and management of osteoporosis (Tables 2 and 3 ) [ 21 – 23 , 37 , 56 – 64 ]. All studies were conducted on ovariectomized (OVX) animal models including mice [ 22 , 23 , 37 , 56 ], rats [ 21 , 57 – 60 , 62 , 64 ], and rabbits [ 61 , 63 ].…”

“…Several studies have demonstrated the effectiveness of platelet concentrates for the treatment and management of osteoporosis (Tables 2 and 3 ) [ 21 – 23 , 37 , 56 – 64 ]. All studies were conducted on ovariectomized (OVX) animal models including mice [ 22 , 23 , 37 , 56 ], rats [ 21 , 57 – 60 , 62 , 64 ], and rabbits [ 61 , 63 ]. In these studies, the systemic and localized application of platelet concentrates (PRP or PRF) alone or in combination with osteoinductive and osteoconductive biomaterials has been investigated [ 21 , 37 , 57 , 58 , 60 – 64 ].…”

“…In this section, our aim is to provide a thorough evaluation of the outcomes related to the use of PDBs for osteoporosis when administered throughout the body. In this regard, Sheu et al [ 23 ] have recently evaluated the effect of intravenous (IV) injection of PRFr, adipose-derived stem cells (ADSCs), and a combination of bon on the tibial growth plate of OVX mice. The IV injections were performed weekly for four consecutive weeks, and then the radiographical and histopathological results were obtained in the 8 th week after the first injection [ 23 ].…”